Growth Hormone Deficiency Market is predicted to reach USD 6.43 billion at a CAGR of 8.86% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Growth Hormone Deficiency Market”.

Market Research Future (MRFR) has published a cooked research report on the “Global Growth Hormone Deficiency Market” that contains the information from 2019 to 2032. The Growth Hormone Deficiency market is estimated to register a CAGR of 8.86% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the Global Growth Hormone Deficiency Market— Novo Nordisk A/S (Denmark), Pfizer, Inc. (US), Merck KGaA (Germany), Eli Lily and Company (Netherlands), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Ispen Pharma (Switzerland), Ferring Pharmaceuticals (Switzerland), AnkeBio Co., Ltd (China), and Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China).

Analyst Comment –

“The growth hormone deficiency market is poised for substantial growth, fueled by rising awareness, improved diagnostics, and a growing emphasis on personalized medicine. As research continues to uncover new treatment modalities and therapeutic innovations, the market is expected to witness sustained expansion, addressing unmet needs in patient care, and contributing to the overall advancement of endocrine healthcare.”  

Market Highlights

The global Growth Hormone Deficiency market is expected to register a CAGR of 8.86% during the forecast period and is estimated to reach USD 6.43 billion by 2032.

The growth of the global growth hormone deficiency market is expected to be driven by the increasing number of individuals suffering from growth hormone deficiency (GHD), rising awareness regarding the effectiveness of GH along with clinical trials focused on the safety and efficacy of GHD, and the changing lifestyle along with the growing prevalence of genetic disorders. However, the high cost of treatment and increasing counterfeit products being used for the treatment are restraining the market growth. On the other hand, the collaboration of major players with small players, coupled with a rise in the innovation marked by prominent players, poses lucrative opportunities for the global growth hormone deficiency market.

Segment Analysis

The global growth hormone deficiency market has been segmented based on brand, application, route of administration, and distribution channel.

On the basis of brand, the market is segmented into Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and others. The others segment held the majority share in the market in 2022. Others include Nutropin, Jintropin, Growject, Hormotrop, Tev-tropin, Nutropinaq, Zomacton, and Eutropin.

On the basis of the application, the market is segmented into paediatric growth hormone deficiency, idiopathic short stature, small for gestational age, turner syndrome, adult growth hormone deficiency, prader-willi syndrome, and others. The paediatric growth hormone deficiency segment dominated the market in 2022. Growth hormone deficiency is a rare condition that affects less than one in 3,000 to one in 10,000 children in the US, according to the American Academy of Paediatrics.

On the basis of the route of administration, the market is segmented into subcutaneous, intramuscular, and intravenous. The subcutaneous segment dominated the market in 2022. The segment growth is increasing as it leads to a significant rise in growth rates in patients and a low incidence of antibody development. The majority of the GHD drugs are administered through subcutaneous ROA (Route of Administration). For instance, brands such as Norditropin, Genotropin, Humatrope, Omnitrope, Nutropin, and Saizen are administered subcutaneously.

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, clinics, and e-commerce websites. The hospital pharmacies segment dominated the market in 2022. Recombinant growth hormone is a prescription medication made available only with a prescription of a physician. Moreover, most hospitals have a policy that patients ought to buy medications prescribed by the practitioners from their premises only. Additionally, high investments by governments for the development of advanced healthcare centers and hospitals in various countries are also contributing to the distribution of growth hormone medicines through hospital pharmacies.

Access full report @ https://www.marketresearchfuture.com/reports/growth-hormone-deficiency-market-10430

Regional Analysis

The global growth hormone deficiency market, based on region, has been divided into Americas, Europe, Asia-Pacific, and Middle East & Africa. Americas consists of North America and Latin America. The Europe growth hormone deficiency market comprises of Western Europe and Eastern Europe. The growth hormone deficiency market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Middle East & Africa growth hormone deficiency market comprises of Middle East and Africa.

The Americas growth hormone deficiency market accounted for the largest market share in 2022. Key factors attributed to its large share include developed healthcare infrastructure, increasing technological advancement, and the presence of many market players in the region.

The European growth hormone deficiency market comprises Eastern Europe and Western Europe. Western Europe comprises countries such as Germany, the UK, France, Italy, and Spain. The European market is expected to be the second-largest growth hormone deficiency market. The market growth in this region is attributed to the rising occurrences of growth hormone deficiencies, increasing preference for growth hormones in the treatment of idiopathic short stature (ISS), and rising government expenditure for the healthcare sector. According to the data suggested by the Eurostat, it is observed that among the EU member states, healthcare expenditure in France and Germany was equivalent to 11.3% of GDP in 2017, a larger share than in any other EU member state. The next highest ratio was observed in Sweden (11.0%).

Furthermore, Asia-Pacific is anticipated to be the fastest-growing market owing to the growing healthcare expenditure and the presence of a large patient pool. Growing investments by market players in the region due to the increasing demand are expected to contribute to the growth of the market. For instance, in March 2017, Novo Nordisk initiated a phase 3 clinical trial of somapacitan (NNC0195-0092) for Adult Growth Hormone Deficiency (AGHD) in Japan. Additionally, the rising awareness about the efficiency of growth hormone therapy in short stature is likely to increase the demand for growth hormone products in this region.

Moreover, the Middle East & Africa market have increasing healthcare expenditure, rising investments by major market players, and growing patient pool in this region. For instance, according to the International Trade Administration, health expenditure in the UAE was USD 17 billion in 2017 and is expected to reach USD 21.3 billion by 2021. The increasing prevalence of growth hormones is expected to contribute to the growth of the market.

Key Findings of the Study

• The global growth hormone deficiency market is expected to reach USD 6.43 billion by 2032, at a CAGR of 8.86% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market.


• Based on distribution channel, the hospitals pharmacies segment was attributed to holding the largest market in 2022.


• Novo Nordisk A/S (Denmark), Pfizer, Inc. (US), Merck KGaA (Germany), Eli Lily and Company (Netherlands), Novartis AG (Switzerland) are the key market players.